A comparison of dehydration effects of V2-antagonist (OPC-31260) on the inner ear between systemic and round window applications

Objective. To evaluate the cutaneous and the inner ear tolerance of bioactive glass S53P4 when used in the mastoid and epitympanic obliteration for chronic otitis surgery.Material and Methods. Forty-one cases have been included in this prospective study. Cutaneous tolerance was clinically evaluated 1 week, 1 month, and 3 months after surgery with a physical examination of the retroauricular and external auditory canal (EAC) skin and the presence of otalgia; the inner ear tolerance was assessed by bone-conduction hearing threshold 1 day after surgery and by the presence of vertigo or imbalance.Results. All surgeries but 1 were uneventful: all patients maintained the preoperative bone-conduction hearing threshold except for one case in which the round window membrane was opened during the dissection of the cholesteatoma in the hypotympanum and this led to a dead ear. No dizziness or vertigo was reported. Three months after surgery, healing was achieved in all cases with a healthy painless skin. No cases of revision surgery for removal of the granules occurred in this study.Conclusion. The bioactive glass S53P4 is a well-tolerated biomaterial for primary or revision chronic otitis surgery, as shown by the local skin reaction which lasted less than 3 months and by the absence of labyrinthine complications.

Download Full-text

Inner Ear Pathology and Otitis Media

Annals of Otology Rhinology & Laryngology ◽

10.1177/00034894800890s358 ◽

1980 ◽

Vol 89 (3_suppl) ◽

pp. 249-253 ◽

Cited By ~ 34

Author(s):

Michael M. Paparella ◽

Marcos V. Goycoolea ◽

William L. Meyerhoff

Keyword(s):

Inner Ear ◽

Otitis Media ◽

Round Window ◽

Round Window Membrane

Insidious inner ear complications of otitis media have been and are being studied in our laboratory. The purpose of this paper is to review these studies, coordinate, capsulize and highlight the results with emphasis on the transport role of the round window membrane.

Download Full-text

Comparison of gentamicin distribution in the inner ear following administration via the endolymphatic sac or round window

The Laryngoscope ◽

10.1002/lary.21041 ◽

2010 ◽

Vol 120 (10) ◽

pp. 2054-2060 ◽

Cited By ~ 9

Author(s):

Yiliang Zhang ◽

Ru Zhang ◽

Chunfu Dai ◽

Peter S. Steyger ◽

Yongfu Yu

Keyword(s):

Inner Ear ◽

Round Window ◽

Endolymphatic Sac

Download Full-text

Common drugs used in ENT

Oxford Handbook of ENT and Head and Neck Surgery ◽

10.1093/med/9780199550791.003.21 ◽

2009 ◽

pp. 347-350

Author(s):

Rogan Corbridge ◽

Nicholas Steventon

Keyword(s):

Inner Ear ◽

Tympanic Membrane ◽

Middle Ear ◽

Otitis Externa ◽

Round Window ◽

Acid Reflux ◽

Tympanic Membrane Perforation ◽

Active Infection ◽

Middle Ear Mucosa ◽

Membrane Perforation

Drugs used in the ear 348 Drugs used in the nose 349 Drugs used in the treatment of acid reflux 350 This group of drugs is widely used for the treatment of otitis externa. Otitis externa 2 drops tds for 10 days Presence of grommet or tympanic membrane perforation due to aminoglycoside ototoxicity in the inner ear. Risk thought to be low in the presence of active infection where the middle-ear mucosa is swollen and the antibiotic is unlikely to reach the inner ear via the round window...

Download Full-text

Eradicating Otomycosis with Terbinafine Solution: Basic and Clinical Investigation

Audiology and Neurotology ◽

10.1159/000501540 ◽

2019 ◽

Vol 24 (4) ◽

pp. 183-190

Author(s):

Ting-Hua Yang ◽

Yi-Ho Young

Keyword(s):

Clinical Practice ◽

Inner Ear ◽

Morphological Study ◽

Antifungal Agents ◽

Clinical Investigation ◽

Round Window ◽

Round Window Membrane ◽

Potential Candidate ◽

Potential Treatment ◽

Total Dosage

Background: Otomycosis still remains intractable in clinical practice, likely because topical antifungal agents lack efficacy or are potentially toxic to the inner ear end organs. Objectives: The aim of this study was to investigate whether terbinafine solution is a potential candidate for treating intractable otomycosis in humans. In addition, the toxic effect on the inner ear was also assessed by animal models treated with terbinafine. Methods: Guinea pigs were instilled with 0.1 mL terbinafine (10 and 25 mg/mL) in the left round window membrane. At 2 weeks after treatment, all animals underwent an inner ear test battery and were then sacrificed for morphological study. Clinically, 20 patients with otomycosis were treated with terbinafine solution at a dosage of 0.4 mg. Results: All terbinafine-treated animals showed intact inner ear function when total dosage of terbinafine was <2.5 mg, which was further confirmed by morphological study. Subsidence of otomycosis was achieved in all 20 patients 1 week after treatment with terbinafine (0.4 mg) without untoward effect. No evidence of recurrence was noted 1 year after treatment. Conclusion: The paucity of inner ear toxicity of terbinafine even at a dosage of 2.5 mg was identified in guinea pig models morphologically and physiologically. Topical application of terbinafine solution at a dosage of 0.4 mg may be a potential treatment for otomycosis in humans.

Download Full-text

Intratympanic Steroid Treatment of Inner Ear Disease and Tinnitus (Preliminary Report)

Ear Nose & Throat Journal ◽

10.1177/014556139607500806 ◽

1996 ◽

Vol 75 (8) ◽

pp. 468-488 ◽

Cited By ~ 127

Author(s):

Herbert Silverstein ◽

Daniel Choo ◽

Seth I. Rosenberg ◽

Jeffery Kuhn ◽

Michael Seidman ◽

...

Keyword(s):

Inner Ear ◽

Round Window ◽

Meniere’S Disease ◽

Menière’S Disease ◽

Round Window Membrane ◽

Meniere's Disease ◽

Ménière’S Disease ◽

Menière's Disease ◽

Inner Ear Disease ◽

Ménière's Disease

Intratympanic instillation of Depo-Medrol® (80 mg/cc), dexamethasone ophthalmic solution (1 mg/cc), or dexamethasone intravenous (4 mg/cc) solution produces improvement of cochlear function in certain patients with Meniere's disease, autoimmune inner ear disease and sudden sensorineural deafness. Tinnitus improved in 47%, most often in patients with Meniere's disease (9 of 15; 60%). The SRT improvement of greater than 10 dB or SD greater than 15% was documented in 41% (average improvement in SRT: 15 dB; SD: 24%). Patients with tinnitus and bilateral sensorineural hearing loss (i.e., presbycusis) did not benefit from the treatment. Prior to treatment with intratympanic medication, laser-assisted tympanostomy with middle ear exploration, using otoendoscopy to determine the status of the round window niche and remove mucosal folds, helps in making the round window membrane accessible to local application of drops. Placing Gelfoam into the round window niche under direct vision, and using a Venturi Bobbin tube in the tympanic membrane, appears to be a satisfactory method for delivering medication to the inner ear fluids. The medication can be injected by the physician through the tube into the middle ear, or the patient can perform self-treatment at home, placing medication in the external auditory canal. A double-blind, cross-over study in patients with Meniere's disease is now in progress with Institutional Review Board (IRB) approval, which will be reported at a later date. This preliminary study has shown that intratympanic steroids may affect the symptoms of hearing loss and tinnitus in patients with various inner ear problems. Patients with Meniere's disease appear to respond in the highest percentage of cases. Hopefully, additional research will suggest the appropriate drugs which can be used to treat inner ear disease. Direct application of the drug to the round window membrane may increase the concentration in the inner ear fluids, thus avoiding the systemic effects.

Download Full-text